Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
A pharmacology primer : techniques for more effective and strategic drug discovery / Terry P. Kenakin
| A pharmacology primer : techniques for more effective and strategic drug discovery / Terry P. Kenakin |
| Autore | Kenakin, Terrence P. <1949- > |
| Edizione | [4. ed] |
| Pubbl/distr/stampa | Amsterdam ... [etc.] : Academic press, c2014 |
| Descrizione fisica | xix, 430 p. : ill. ; 29 cm |
| Disciplina | 615.7 |
| Soggetto non controllato | Farmacologia sperimentale |
| ISBN | 9780124076631 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910271459103321 |
Kenakin, Terrence P. <1949- >
|
||
| Amsterdam ... [etc.] : Academic press, c2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The ADME encyclopedia : a comprehensive guide on biopharmacy and pharmacokinetics / / edited by Alan Talevi
| The ADME encyclopedia : a comprehensive guide on biopharmacy and pharmacokinetics / / edited by Alan Talevi |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (1209 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Pharmacokinetics
Farmacocinètica |
| Soggetto genere / forma |
Enciclopèdies electròniques
Llibres electrònics |
| ISBN |
9783030848606
9783030848590 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910578693903321 |
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME Processes in Pharmaceutical Sciences : Dosage, Design, and Pharmacotherapy Success / / edited by Alan Talevi, Pablo A. M. Quiroga
| ADME Processes in Pharmaceutical Sciences : Dosage, Design, and Pharmacotherapy Success / / edited by Alan Talevi, Pablo A. M. Quiroga |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (X, 362 p. 88 illus., 67 illus. in color.) |
| Disciplina | 615.7 |
| Soggetto topico |
Pharmaceutical technology
Pharmaceutical Sciences/Technology |
| ISBN | 3-319-99593-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1 The Basics of ADME Processes -- Introduction ADME Processes and Their Relationship with Pharmaceutical Practice -- Drug Release -- Drug Adsorption -- Drug Excretion.-Routes of Administration -- Part 2 The Importance of ADME Properties in Burgeoning Pharmaceutical Topics -- Nanotechnology and Drug Delivery -- Pharmacogenomics and Indiviualized Therapy -- Bioavailability and Bioequivalence Studies -- The Absorption and Distribution of Biopharmaceuticals/Biological Medical Products -- Drug-Drug and Food-Drug Interactions of Pharmacokinetic Nature -- In silico and In vitro ADME prediction -- Drug Transporters and Multi-drug Resistance. |
| Record Nr. | UNINA-9910298397303321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in Pharmacokinetics and Pharmacodynamics / / edited by Panos Macheras
| Advances in Pharmacokinetics and Pharmacodynamics / / edited by Panos Macheras |
| Autore | Macheras Panos |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (208 pages) |
| Disciplina | 615.7 |
| Collana | AAPS Introductions in the Pharmaceutical Sciences |
| Soggetto topico |
Drug delivery systems
Drugs—Design Pharmaceutical chemistry Metabolism Pharmacology Clinical biochemistry Drug Delivery Structure-Based Drug Design Pharmaceutics Medical Biochemistry |
| Soggetto non controllato |
Therapeutics
Medical |
| ISBN |
9783031295416
9783031295409 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Pharmacokinetics -- Chapter 1: Current status in PBPK modeling -- Chapter 2: Physiologically based biopharmaceutics modeling (PBBM) Application on Food Effect Assessment -- Chapter 3: Physiologically based finite time pharmacokinetic (PBFTPK) models: Inception and development -- Chapter 4: Physiologically based finite time pharmacokinetic (PBFTPK) models: Applications -- Pharmacodynamics -- Chapter 5: Pharmacokinetic – Pharmacodynamic Modelling and Simulation in Clinical Practice and Studies -- Chapter 6: On the Verge of Impossibility: Accounting for Variability Arising from Permutations of Comorbidities that Affect the Fate of Drugs in the Human Body -- Chapter 7: Impact of Clinical Pharmacology on the Modernization of Drug Development and Regulation. |
| Record Nr. | UNINA-9910728396903321 |
|
Macheras Panos
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advancing healthcare through personalized medicine / / Priya Hays
| Advancing healthcare through personalized medicine / / Priya Hays |
| Autore | Hays Priya <1968-> |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (755 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Precision medicine
Medicina personalitzada |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-80100-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface to the Second Edition -- Acknowledgments -- Contents -- 1: "Introduction: Biomedical Innovation and Policy in the Twenty-First Century" -- Liquid Biopsy -- Challenges and Incentives for Implementation -- Components of the Book -- References -- 2: "The Rise of Genomics and Personalized Medicine" -- Human Genome Project, Sequencing, and Genomic Medicine -- New Innovative Studies in NGS -- Sanger Sequencing and Comparison with NGS -- Single-Cell RNA Sequencing -- Single-Cell Epigenetic Analysis -- Application of Single-Cell Analysis in Precision Cancer Therapy -- Genomic Medicine -- Genomic Sequencing for Assessment of Disease -- Potential Challenges of Genomic Medicine -- ENCODE: Mapping the Functional Genome -- Pharmacogenetics: Pharmacogenomics -- Thiopurine-Methyltransferase (TPMT) -- CYP2D6 -- CYP2C9 -- UDP-Glucoronyltransferase -- HIV and Abacavir -- Targeted Panel Sequencing -- Genomics-Enabled Medicine for Cancer Prognosis -- The Emergence of Personalized Medicine -- Biomarker Discovery -- Tumor Mutational Burden (TMB) as a Biomarker -- Germline Considerations -- Conclusion -- References -- 3: "Patient Narratives: Personalized Medicine in the Field" -- The Population of 1 Trial: The Story of Milasen -- The Narratives of Personalized Medicine -- Social Media's Avenues for Personalized Medicine -- Social Media for Patient Engagement -- Role of Twitter in Identifying Barriers to Care Among Patients with Metastatic Breast Cancer [6] -- The Narrative of Xin Zheng: A Lung Cancer Success Story -- References -- 4: Alliances: Knowledge Infrastructures, and the Digitization of Precision Health -- Precision Medicine: Its Potential Development and Implementation -- Implications of Precision Medicine for Patient Care and Disease Treatment -- Monitoring the Personal Genome -- Macroeconomic Considerations of Precision Medicine.
Global Alliance for Genomics and Health -- Updates to Global Alliance for Genomics and Health: GA4GH 2020 (Figs. 4.7, 4.8, 4.9, and 4.10) -- Systems Thinking and -Omics Technologies -- Data Portals and Data Analysis -- Bridging the Gap for Translational Genomic Research -- Database Efforts -- Genomics and Artificial Intelligence -- Deep Learning Methods in Precision Medicine -- Digital Precision Health: The History of Machine Learning and the Power of Big Data for Clinical Medicine -- Digital Pathology -- Conclusion -- References -- 5: "Great Strides in Precision Medicine: Personalized Oncology, Immunotherapies, and Molecular Diagnostics" -- An Immunotherapy Case Report -- A Target Therapy Case Report -- The Basis for Targeted Therapies: Acquired Mutations and Biomarkers in Cancers -- Oncogenesis -- Implications of Tumor Heterogeneity -- Enrichment and Adaptive Strategies -- Molecular Abnormalities in Solid Tumors -- Germline Molecular Testing for Hereditary Cancer Risk -- Cell Cycle Checkpoints -- Understanding Clinical Trials in the Era of Precision Oncology: Data, Biomarkers, and Diagnostic Testing -- Analysis -- Action -- N of 1 Trial -- Tumor Subtypes -- Breast Cancer -- Incidence and Mortality -- Inherited Breast Cancer -- Targeted Therapy Options in Breast Cancer Care -- Tyrosine Kinase Inhibitor: Tucatinib -- HER2+ /HER2-Positive Breast Cancer -- Triple-Negative Breast Cancer (TNBC) and Metastatic Breast Cancer (mBC) -- Biomarker Predicting Response to PARP Inhibitors -- "Study Supports Using MRD as a Stratification Variable for Patients with TNBC" -- "Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer" -- Olaparib -- Talazoparib -- Immunotherapy and Immunotherapy Combinations -- Newer Generation Targeted Therapy Agents -- Abemaciclib -- Other Combination Agents -- Recent Immunotherapies. Tecentriq -- Pembrolizumab -- Avelumab -- Liquid Biopsy in Breast Cancer: A Systematic Review -- Current Breast Cancer Diagnosis Standards -- Oncotype DX -- MammaPrint -- PAM50 (Prosigna) -- Genomic Grade Index (GGI) (Ipsogen) -- Veridex Rotterdam Signature 76 Genes -- Ventana HER2 Dual ISH DNA Probe Cocktail Assay for Detection of HER2 -- RSClin TOOL: 21-Gene Recurrence Score (RS) -- HER2DX -- Signatera MRD Test -- Findings for Protein-Truncating and Missense Variants -- "Study Suggests 86-SNV Be Incorporated in Breast Cancer Risk Prediction Models" -- Conclusion -- Colorectal Cancer -- Incidence and Mortality -- Colorectal Cancer Classification Systems -- Molecular Pathology and Diagnosis of Colorectal Cancer -- "Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile" -- Inherited CRC Syndrome -- Hereditary Nonpolyposis Colorectal Carcinoma (Lynch Syndrome) -- Familial Adenomatous Polyposis -- De Novo Colorectal Cancer -- BRAF V600E -- Additional CRC Biomarkers and Mutations -- Targeted and Immunotherapies -- Bevacizumab -- Cetuximab -- Panitumumab -- Ramucirumab -- Ziv-aflibercept -- ASPECCT Trial [76] -- Immunotherapies for CRC: A Recent Development -- Immunotherapy for the Nonimmunogenic Tumors -- Liquid Biopsy -- Conclusion -- Melanoma -- Incidence and Mortality -- Targeted Therapies -- BRAF-V600E Inhibitors -- Immunotherapies for Melanoma -- Multicenter Double-Blind Phase III IMMUNED Trial -- The Phase III Double-Blind EORTC 1325/KEYNOTE-054 Trial (continued) -- Immunotherapies in Combination with Targeted Agents -- Adoptive Cell Therapy for Metastatic Melanoma -- Liquid Biopsy -- "Pretreatment ctDNA May Help Predict Outcomes With First-Line-but Not Second-Line-Immunotherapy for Patients With Melanoma" -- Management of Brain Metastases from cuM -- Conclusion -- Lung Cancer -- Incidence and Mortality. Targeted Therapies -- "Pyrotinib for Pretreated Patients with HER2-Mutated Advanced NSCLC" -- Erlotinib -- Gefitinib -- Afatinib -- Capmatinib -- Dacomitinib -- Summary of Erlotinib, Gefitinib, and Afatinib -- Sotorasib -- Ceritinib -- Alectinib -- Brigatinib -- Lorlatinib -- Selpercatinib -- Pralsetinib -- Newer Targeted Therapy Agents -- Osimertinib -- Tepotinib -- Use of Liquid Biopsy in the Trial -- Poziotinib -- Ramucirumab/Erlotinib -- Mobocertinib -- Capmatinib -- Brigatinib -- Adagrasib -- Immunotherapies -- Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC -- KEYNOTE-024 -- KEYNOTE-042 -- KEYNOTE-189 -- KEYNOTE-407 -- KEYNOTE Trials Adverse Events -- IMpower Trials -- IMpower 110 -- IMpower 130 -- IMpower 131 -- IMpower 150 -- Durvalumab -- Comparative Analysis of Pembrolizumab or Nivolumab in NSCLC -- The ORIENT-11 Trial Showed Sintilimab Plus Chemotherapy Improves PFS in Advanced NSCLC -- The PD-L1 Status Dilemma -- CheckMate Trials -- CheckMate 227 -- CheckMate 9LA -- Molecular Diagnosis -- Molecular Genotyping in NSCLC -- Role of Plasma-Based Molecular Genotyping in NSCLC -- Liquid Biopsy -- Case Studies of Liquid Biopsy in Lung Cancer -- Case Study 1 -- Case Study 2 -- Case Study 3 -- Case Studies 4 and 5 -- Case Study 6 -- Conclusion -- Prostate Cancer -- Incidence and Mortality -- Genomic Medicine and Sequencing -- Newer Generation Targeted Therapies -- Prostate-Specific Membrane Antigen -- PARP Inhibitors -- "Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer" -- Rucaparib -- Non-metastatic Prostate Cancer -- PROSPER -- SPARTAN -- ARAMIS -- Summary of PROSPER, SPARTAN, and ARAMIS -- Immunotherapies -- Molecular Diagnosis -- Liquid Biopsy -- Genetic Screening -- Which Men Should Be Evaluated for Prostate Cancer?. Key Genomic Differences Identified in the Prostate Cancer of African-American Men -- "Series of Studies Identify Genetic Risk Factors for Prostate Cancer" -- "17q22 Loss Associated With Survival in Enzalutamide-Resistant mCRPC" -- Racial Differences in Genomic Profiles of Primary and Metastatic Prostate Cancer -- "Study Finds Differences in BRCA1/2 Male Pathogenic Variant Carriers" -- Diagnostic Tests -- 4 k Score -- Prostate Health Index (PHI) -- Prostate Cancer Antigen 3 Assay (PCA3) -- SelectMDx -- ExoDx Prostate Intelliscore (EPI) -- ConfirmMDx -- Prognostic Tests -- Decipher (GC) -- Post-operative Radiation Therapy Outcomes Score -- Promark -- Prolaris -- OncotypeDx Genomic Prostate Score (GPS) -- Precision Imaging -- Conclusion -- Central Nervous System Tumors -- Incidence and Mortality -- Molecular Classification of Glioblastoma -- Diffuse Astrocytic and Oligodendroglial Tumors -- IDH-Mutated Astrocytomas -- Biomarkers and Targeted Therapies -- Tumor Immunology -- Subset of Glioblastoma Tumors Identified as Immunotherapy Candidate -- Meningiomas -- Hemangioblastomas -- Conclusion -- Hematological Malignancies -- Incidence and Mortality -- Hematologic Oncology Highlights 2019-2020 Almanac -- Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia -- Study Finds Asciminib Safer and More Effective than TKI Bosutinib in Chronic Phase CML -- "Effects of Stopping Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia: -- Focus on Molecular Response and Patient-Reported Outcomes" -- "First-Line Dasatinib Plus Blinatumomab for Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" -- Clinical Trials Investigating the Efficacy and Safety of the Novel CART Therapies UCART 19 and UCART22 in R/R B-Cell ALL -- "Chemotherapy Plus Blinatumomab for Philadelphia Chromosome-Negative B-Cell ALL". "FDA Grants Fast Track Designation to Allogeneic CAR T-Cell Therapy for Advanced ALL". |
| Record Nr. | UNINA-9910502660103321 |
|
Hays Priya <1968->
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Amorphous Solid Dispersions : Theory and Practice / / edited by Navnit Shah, Harpreet Sandhu, Duk Soon Choi, Hitesh Chokshi, A. Waseem Malick
| Amorphous Solid Dispersions : Theory and Practice / / edited by Navnit Shah, Harpreet Sandhu, Duk Soon Choi, Hitesh Chokshi, A. Waseem Malick |
| Edizione | [1st ed. 2014.] |
| Pubbl/distr/stampa | New York, NY : , : Springer New York : , : Imprint : Springer, , 2014 |
| Descrizione fisica | 1 online resource (702 p.) |
| Disciplina | 615.7 |
| Collana | Advances in Delivery Science and Technology |
| Soggetto topico |
Pharmaceutical technology
Pharmaceutical Sciences/Technology |
| ISBN | 1-4939-1598-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Fundamentals of Amorphous Systems: Thermodynamic Aspects -- 2 Theoretical Considerations in Developing Amorphous Solid Dispersions -- 3 Overview of Amorphous Solid Dispersion Technologies -- 4 Excipients for Amorphous Solid Dispersions -- 5 Miniaturized Screening Tools for Polymer and Process Evaluation -- 6 HME for Solid Dispersions: Composition and Design Considerations -- 7 HME for Solid Dispersions: Scale up and Late Stage Development -- 8 Spray Drying: Scale UP and Manufacturing -- 9 Design and Development of HPMCAS based spray dried dispersions -- 10 MBP Technology: Composition and Design Considerations -- 11 MBP Technology: Process Development and Scale up -- 12 Pharmaceutical Development of MBP Solid Dispersions: Case Studies -- 13 Downstream Processing Considerations -- 14 Structural Characterization of Amorphous Solid Dispersions -- 15 Dissolution of Amorphous Solid Dispersions: Theory and Practice -- 16 Stability of Amorphous Solid Dispersion -- 17 Regulatory Considerations in Development of Amorphous Solid Dispersions -- 18 KinetiSol® based Amorphous Solid Dispersions -- 19 Amorphous Solid Dispersion Using Supercritical Fluid Technology -- 20 Supersolubilization by Using Non-Salt Forming Acid-Base Interaction -- 21 Stabilized Amorphous Solid Dispersions with Small Molecule Excipients -- 22 Mesoporous ASD – Fundamentals -- 23 Mesoporous Silica Drug Delivery Systems. |
| Record Nr. | UNINA-9910298352103321 |
| New York, NY : , : Springer New York : , : Imprint : Springer, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analytical characterization of biotherapeutics / / edited by Jennie R. Lill, Wendy N. Sandoval
| Analytical characterization of biotherapeutics / / edited by Jennie R. Lill, Wendy N. Sandoval |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2017 |
| Descrizione fisica | 1 online resource |
| Disciplina | 615.7 |
| Soggetto topico |
Proteins - Therapeutic use
Proteins - Analysis |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-119-38440-0
1-119-38442-7 1-119-38443-5 |
| Classificazione | SCI013010 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Machine generated contents note: Dedication Chapter 1: Introduction to Biotherapeutics Jennie R. Lill Chapter 2: Mass Spectrometric Characterization of Recombinant Proteins Corey E Bakalarski, Wendy N Sandoval & Jennie R Lill Chapter 3: Characterizing the Termini of Recombinant Proteins Nestor Solis, Christopher M. Overall Chapter 4: Assessing activity & conformation of recombinant proteins Diego Ellerman, Till Maurer, Justin M. Scheer Chapter 5: Structural Characterization of Recombinant Proteins & Antibodies Paola Di Lello and Patrick Lupardus Chapter 6: Antibody de novo sequencing Natalie Castellana, Adrian Guthals Chapter 7: Characterization of Antibody Drug Conjugates Yichin Liu Chapter 8: Characterization of Bi-Specific or other Hybrid molecules T. Noelle Lombana and Christoph Spiess Chapter 9: Bio-Repository Anne Baldwin, Kurt Schroeder, Lovejit Singh, Karen Billeci Chapter 10: Characterization of Manufacturing Host-Cell Contaminant Proteins Denise Krawitz, Jason Rouse, Justin Sperry, Wendy Sandoval, Martin Vanderlaan Chapter 11: Analytical Tools for Biologics Molecular Assessment Wilson Phung , Wendy Sandoval, Robert F Kelley & Jennie R Lill Chapter 12: Glycan Characterization: Determining the Structure, Distribution, and Localization of Glycoprotein Glycans John Briggs INDEX. |
| Record Nr. | UNINA-9910271008203321 |
| Hoboken, New Jersey : , : Wiley, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Analytical characterization of biotherapeutics / / edited by Jennie R. Lill, Wendy N. Sandoval
| Analytical characterization of biotherapeutics / / edited by Jennie R. Lill, Wendy N. Sandoval |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2017 |
| Descrizione fisica | 1 online resource |
| Disciplina | 615.7 |
| Soggetto topico |
Proteins - Therapeutic use
Proteins - Analysis |
| ISBN |
1-119-38440-0
1-119-38442-7 1-119-38443-5 |
| Classificazione | SCI013010 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Machine generated contents note: Dedication Chapter 1: Introduction to Biotherapeutics Jennie R. Lill Chapter 2: Mass Spectrometric Characterization of Recombinant Proteins Corey E Bakalarski, Wendy N Sandoval & Jennie R Lill Chapter 3: Characterizing the Termini of Recombinant Proteins Nestor Solis, Christopher M. Overall Chapter 4: Assessing activity & conformation of recombinant proteins Diego Ellerman, Till Maurer, Justin M. Scheer Chapter 5: Structural Characterization of Recombinant Proteins & Antibodies Paola Di Lello and Patrick Lupardus Chapter 6: Antibody de novo sequencing Natalie Castellana, Adrian Guthals Chapter 7: Characterization of Antibody Drug Conjugates Yichin Liu Chapter 8: Characterization of Bi-Specific or other Hybrid molecules T. Noelle Lombana and Christoph Spiess Chapter 9: Bio-Repository Anne Baldwin, Kurt Schroeder, Lovejit Singh, Karen Billeci Chapter 10: Characterization of Manufacturing Host-Cell Contaminant Proteins Denise Krawitz, Jason Rouse, Justin Sperry, Wendy Sandoval, Martin Vanderlaan Chapter 11: Analytical Tools for Biologics Molecular Assessment Wilson Phung , Wendy Sandoval, Robert F Kelley & Jennie R Lill Chapter 12: Glycan Characterization: Determining the Structure, Distribution, and Localization of Glycoprotein Glycans John Briggs INDEX. |
| Record Nr. | UNINA-9910830599403321 |
| Hoboken, New Jersey : , : Wiley, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibacterial agents [Risorsa elettronica] : chemistry, mode of action, mechanisms of resistance, and clinical applications / Rosaleen Anderson ... [et al.]
| Antibacterial agents [Risorsa elettronica] : chemistry, mode of action, mechanisms of resistance, and clinical applications / Rosaleen Anderson ... [et al.] |
| Pubbl/distr/stampa | Chichester, West Sussex : John Wiley & Sons, 2012 |
| Disciplina | 615.7 |
| Soggetto non controllato | Agenti antibatterici |
| ISBN | 9781118325421 |
| Formato | Risorse elettroniche  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990009793850403321 |
| Chichester, West Sussex : John Wiley & Sons, 2012 | ||
| Risorse elettroniche | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Anticoagulation : Current Perspectives / / edited by Xingshun Qi, Xiaozhong Guo
| Anticoagulation : Current Perspectives / / edited by Xingshun Qi, Xiaozhong Guo |
| Pubbl/distr/stampa | London : , : IntechOpen, , 2022 |
| Descrizione fisica | 1 online resource (138 pages) : illustrations |
| Disciplina | 615.7 |
| Soggetto topico | Anticoagulants (Medicine) |
| ISBN | 1-80355-892-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Anticoagulation |
| Record Nr. | UNINA-9910586642503321 |
| London : , : IntechOpen, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
